Vestar Inc. said Monday that animal studies of the company'sDaunoXome, its patented liposomal formulation of theestablished cancer drug daunorubicin, showed a nearly tenfoldincrease in the amount of drug accumulated in tumors,resulting in 10 times greater potency compared with theunencapsulated form of the drug.

The preclinical results, published in the June 15 issue of CancerResearch, substantiate the emerging clinical data from PhaseI/II trials of the drug against solid tumors and Kaposi'ssarcoma, the San Dimas, Calif., company said.

(c) 1997 American Health Consultants. All rights reserved.